Table 1 Characteristics of the included studies

Dimopoulos(2016)

POLLUX

Dimopoulos(2018)

POLLUX

III

569

T:daratumumab16mg/kg + lenalidomide25mg + dexamethasone40mg

C:lenalidomide25mg + dexamethasone40mg

T:13.5

C:13.5

T:25.4

C:25.4

PFS

T:N

C:18.4

T:N

C:17.5

12 Months

T:83.2%C:60.1%

24 Months

T:68.0%C:40.9%

T:24.5

C:16.0

Palumbo(2016)

CASTOR

Palumbo(2018)

CASTOR

III

498

T:daratumumab 16 mg/kg

+bortezomib1.3 mg/m² + dexamethasone20mg

C:bortezomib1.3 mg/m² + dexamethasone20mg

T:7.4

C:7.4

T:19.4

C:19.4

PFS

T:N

C:7.2

T:16.7

C:7.1

12 Months

T:60.7%C:26.9%

18 Months

T:48% C:7.9%

T:13.4

C:5.2

Facon(2019)

NCT02252172

III

737

T:daratumumab16mg/kg + lenalidomide25mg + dexamethasone40mg

C:lenalidomide25mg + dexamethasone40mg

T:28

C:28

PFS

T:N

C:31.9

30 months

T:N

C:N

T:25.3

C:21.3

Mateos(2017)

ALCYONE

Maria(2019)

ALCYONE

III

706

T:daratumumab16mg/kg + bortezomib1.3 mg/m² + melphalan9mg/m² + prednisone 60 mg/m²

C:bortezomib1.3 mg/m² + melphalan9mg/m² + prednisone 60 mg/m²

T:16.5

C:16.5

T:40.1

C:40.1

PFS

T:N

C:18.1

T:36.4

C:19.3

18 months

T:71.6%C:50.2%

36 months

T:50.7%C:18.5%

T:14.7

C:12

Michel (2019)

ICARIA-MM

III

307

T:isatuximab10mg/kg + pomalidomide4mg + dexamethasone 40 mg

C:pomalidomide4mg + dexamethasone40mg

T:11.6

C:11.6

PFS

T:11.5

C:6.5

T:N

C:N

T:9.6

C:5.6

Philippe (2019)

CASSIOPEIA

III

1085

T:daratumumab16mg/kg + bortezomib1.3 mg/m² + thalidomide100mg + dexamethasone40mg

C:bortezomib1.3 mg/m² + thalidomide100mg + dexamethasone40mg

T:18.8

C:18.8

SCR

T:N

C:N

T:N

C:N

T:8.9

C:8.7

Mateos(2019)

KEYNOTE-183

III

249

T: pembrolizumab 200 mg

+pomalidomide 4 mg + dexamethasone40mg

C:pomalidomide 4 mg + dexamethasone40mg

T:8.1

C:8.1

PFS

OS

T:5.6

C:8.4

6 months

T:48%

C:60%

T:4.1

C:4.2

Usmani(2019)

KEYNOTE-185

III

301

T:pembrolizumab200mg + lenalidomide25mg + dexamethasone40mg

C:+lenalidomide25mg + dexamethasone40mg

T:6.6

C:6.6

PFS

T:N

C:N

6 months

T:82%

C:85%

T:4.4

C:N

Andrzej(2016)

NCT01478048

II

152

T:Elotuzumab10mg/kg + bortezomib1.3 mg/m² + dexamethasone20mg

C:bortezomib1.3 mg/m² + dexamethasone20mg

T:15.9

C:11.7

PFS

T:9.7

C:6.9

24 months

T:18%

C:11%

T:N

C:N

Meletios(2018)

ELOQUENT-3

II

117

T:Elotuzumab10-20 mg/kg + pomalidomide4mg

+ dexamethasone40mg

C:pomalidomide4mg + dexamethasone40mg

T:9.1

C:9.1

PFS

T:10.3

C:4.7

T:N

C:N

T:8.4

C:4.7

Sagar(2015)

ELOQUENT-2

Dimopoulos(2018)

ELOQUENT-2

III

646

T:Elotuzumab10mg/kg

+lenalidomide25mg + dexamethasone40mg

C:lenalidomide25mg + dexamethasone40mg

T:24.5

C:24.5

T:46

C:48

PFS

ORR

T: 19.4

C:14.9

T:N

C:N

12 months

T:68%C:57%

24 months

T:41%C:27%

48 months

T:21%C:14%

T: 19

C:14